

**Supplementary Table 1 Results of logistic regression analysis of the relationship between high levels of serum AGEs and high NAFLD-associated steatosis severity moderate/severe pooled)**

<b>Variable</b>	<b>SE</b>	<b>OR (95%CI)</b>	<b>Sensitivity</b>	<b>Specificity</b>	<b>Accuracy</b>
<b>Crude model</b>			0.62	0.61	0.61
Serum Advanced Glycation End Products	0,47	2.64 (1.04- 6.92)			
Intercept	0,31	0.62 (0.33- 1.14)			
<b>Model 1</b>			0.60	0.73	0.64
Serum Advanced Glycation End Products	0.52	3.38 (1.24- 9.98)			
Gender	0.54	0.20 (0.06- 0.57)			
Intercept	0.43	1.50 (0.64- 3.66)			
<b>Model 2</b>			0.71	0.68	0.69
Serum Advanced Glycation End Products	0.55	3.34 (1.17- 10.40)			
Gender	0.57	0.18 (0.05- 0.52)			
Gamma Glutamyl Transferase (U/L)	0.01	1.03 (1.00- 1.06)			
Intercept	0.62	0.54 (0.15- 1.83)			
<b>Model 3</b>			0.78	0.72	0.75
Serum Advanced Glycation End Products	0.61	4.52 (1.44- 16.28)			
Gender	0.61	0.15 (0.04- 0.50)			
Gamma Glutamyl Transferase (U/L)	0.01	1.03 (1.00- 1.06)			
Altered blood glucose ( $\geq 126$ mg/dL)	0.73	5.70 (1.44- 26.59)			
Altered blood glucose ( $110 \leq 125$ mg/dL)	0.64	0.99 (0.27- 3.55)			

Intercept	0.75	0.29 (0.06- 1.20)			
<b>Model 4</b>			0.77	0.77	0.77
Serum Advanced Glycation End Products	0.62	4.66 (1.45- 17.16)			
Gender	0.63	0.14 (0.03- 0.48)			
Gamma Glutamyl Transferase (U/L)	0.01	1.03 (1.00- 1.06)			
Altered blood glucose ( $\geq 126$ mg/dL)	0.77	6.73 (1.59- 34.69)			
Altered blood glucose ( $110 \leq 125$ mg/dL)	0.67	1.06 (0.27- 4.00)			
High cholesterol	0.60	3.49 (1.09- 12.11)			
Intercept	0.82	0.19 (0.03- 0.88)			

---

High cholesterol was defined as use of medication to treat dyslipidemia or LDL cholesterol  $\geq 130$ . SE standard error, OR odds ratio, CI confidence interval.